Foley Represents Nestle Skin Care and Galderma Against Truinject in Successful Institution of Two Inter Partes Reviews of Patents for Injection Training System

17 November 2020 Media Contact: Dan Farrell News
Foley & Lardner is representing Galderma S.A. and Nestle Skin Health, Inc. in two IPR’s at the PTAB, challenging Truinject Corp.'s patents on automated detection of performance characteristics in an injection training system (U.S. Patent Nos. 10,290,231 and 10,290,232) following a district court complaint filed by Truinject based on the patents.  On November 17, 2020, the PTAB granted institution of both IPRs, IPR2020-00935 and -00937 on all challenged claims on the requested grounds.  Galderma S.A., formerly a subsidiary of Nestlé, is a global pharmaceutical company specializing in dermatological treatments and skin care products.  The Foley team includes George Beck, Stephen B. Maebius, Chase Brill, and Kiri Lee Sharon.

Related Services